v3.20.2
Commitments and Contingencies (Details)
 1 Months Ended 9 Months Ended 12 Months Ended
Apr. 30, 2020
Apr. 28, 2020
EUR (€)
Sep. 30, 2020
USD ($)
shares
Sep. 30, 2019
USD ($)
Dec. 31, 2014
shares
Sep. 30, 2020
EUR (€)
Commitments and Contingencies (Details) [Line Items]            
Estimates expense (in Euro) | €   € 40,000        
Aggregate of security deposit     $ 124,000     € 110,000
Accrued an expenses     12,000      
Amount of initial licensing fee     $ 325,000      
Percentage of equity interest     5.00%      
Shares of equity of common stock (in Shares) | shares     7,996      
Maximum aggregate number of shares issuable (in Shares) | shares     29,109      
Number of share held In escrow of common stock (in Shares) | shares     21,832   7,277  
Maximum aggregate amount of cash payments due     $ 3,000,000 $ 2,500,000    
Employee agreement, description the Company entered into an employment agreement with Dr. Matthew David, pursuant to which Dr. David became the Company’s Executive Vice President and Chief Financial Officer effective on May 11, 2020. After the initial three-year term of the employment agreement, the agreement will automatically renew for additional successive one-year periods, unless either party notifies the other in writing at least 90 days before the expiration of the then current term that the agreement will not be renewed. In connection with Dr. David’s employment, the Company granted him stock options to purchase 250,000 shares of common stock, 166,000 of which vest in four equal installments over four years beginning one year after his start date and continuing on each of the next three anniversaries, subject to Dr. David’s continued employment with the Company, and 84,000 of which vest upon the achievement of designated performance milestones, subject to Dr. David’s continued employment with the Company.          
TauroPharm [Member]            
Commitments and Contingencies (Details) [Line Items]            
Aggregate of security deposit     $ 183,000